Jacob McCright

Company: DEKA Biosciences

Job title: Scientist II

Seminars:

Combining DK210 (CD20) With BiTE’s to Block Cytokine Release Syndrome 12:00 pm

Combining anti-CD19 BiTE’s in vitro dramatically enhances T cell cytolysis of tumors when combined with as low as 0.1 ng/mL BiTE concentrations Blunting BiTE mediated cytokine release syndrome Enhancing tumor responses while suppressing CRS, suggesting DK210 (tumor target) may represent a potent combination partner with BiTE platforms Read more

day: Conference Day Two